Aptinyx Inc (NASDAQ:APTX) has earned a consensus rating of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $12.75.

Several brokerages recently issued reports on APTX. Cowen reaffirmed a “buy” rating on shares of Aptinyx in a report on Monday, June 10th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Aptinyx in a report on Tuesday, April 30th. Svb Leerink began coverage on shares of Aptinyx in a report on Thursday, June 20th. They set an “outperform” rating and a $12.00 price target on the stock. Zacks Investment Research upgraded shares of Aptinyx from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Tuesday, July 16th. Finally, ValuEngine upgraded shares of Aptinyx from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Shares of NASDAQ:APTX traded up $0.08 during midday trading on Friday, hitting $3.30. The stock had a trading volume of 2,030 shares, compared to its average volume of 344,108. The stock has a 50-day moving average price of $3.62. The company has a market capitalization of $118.47 million, a P/E ratio of -1.24 and a beta of -0.03. Aptinyx has a fifty-two week low of $2.88 and a fifty-two week high of $32.25.

Aptinyx (NASDAQ:APTX) last issued its earnings results on Monday, August 12th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.16. The company had revenue of $0.93 million during the quarter, compared to analysts’ expectations of $0.95 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%. As a group, analysts anticipate that Aptinyx will post -2.15 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in APTX. BlackRock Inc. boosted its holdings in Aptinyx by 50.2% in the fourth quarter. BlackRock Inc. now owns 1,155,090 shares of the company’s stock valued at $19,105,000 after acquiring an additional 386,018 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Aptinyx by 30.6% in the 4th quarter. Bank of New York Mellon Corp now owns 43,887 shares of the company’s stock worth $726,000 after purchasing an additional 10,284 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Aptinyx by 20.0% in the 4th quarter. Geode Capital Management LLC now owns 107,464 shares of the company’s stock worth $1,777,000 after purchasing an additional 17,914 shares during the last quarter. Bank of America Corp DE raised its position in Aptinyx by 430.0% in the 4th quarter. Bank of America Corp DE now owns 13,213 shares of the company’s stock worth $218,000 after buying an additional 10,720 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in Aptinyx by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after buying an additional 5,652 shares during the last quarter. Institutional investors and hedge funds own 58.30% of the company’s stock.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Further Reading: What is the accumulation/distribution indicator?

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.